omburtamab

Omburtamab is a monoclonal antibody that targets the B7-H3 (CD276) protein, an immune checkpoint molecule overexpressed in various solid tumors, including neuroblastoma and central nervous system (CNS) malignancies. The drug was originally developed as the murine anti-B7-H3 antibody 8H9 and has been further engineered into radiolabeled forms such as iodine-131 omburtamab for targeted radioimmunotherapy. Omburtamab binds to the FG loop of CD276 on tumor cells, facilitating immune-mediated destruction or direct delivery of cytotoxic radiation when conjugated with radioactive isotopes like iodine-131. This mechanism allows for selective targeting of cancer cells while sparing normal tissues. Omburtamab has shown promising results in early-phase clinical trials for CNS/leptomeningeal metastases from neuroblastoma and other B7-H3-expressing tumors, with significant improvements in survival rates observed in treated pediatric patients[1][5][6][7].

Other names

omburtamab